Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.biomaterials.2013.11.035
DC FieldValue
dc.titleAnti-mycobacterial activities of synthetic cationic α-helical peptides and their synergism with rifampicin
dc.contributor.authorKhara, J.S.
dc.contributor.authorWang, Y.
dc.contributor.authorKe, X.-Y.
dc.contributor.authorLiu, S.
dc.contributor.authorNewton, S.M.
dc.contributor.authorLangford, P.R.
dc.contributor.authorYang, Y.Y.
dc.contributor.authorEe, P.L.R.
dc.date.accessioned2014-10-29T01:48:36Z
dc.date.available2014-10-29T01:48:36Z
dc.date.issued2014-02
dc.identifier.citationKhara, J.S., Wang, Y., Ke, X.-Y., Liu, S., Newton, S.M., Langford, P.R., Yang, Y.Y., Ee, P.L.R. (2014-02). Anti-mycobacterial activities of synthetic cationic α-helical peptides and their synergism with rifampicin. Biomaterials 35 (6) : 2032-2038. ScholarBank@NUS Repository. https://doi.org/10.1016/j.biomaterials.2013.11.035
dc.identifier.issn01429612
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/105656
dc.description.abstractThe rapid emergence of multi-drug resistant tuberculosis (TB) and the lack of effective therapies have prompted the development of compounds with novel mechanisms of action to tackle this growing public health concern. In this study, a series of synthetic cationic α-helical antimicrobial peptides (AMPs) modified with different hydrophobic amino acids was investigated for their anti-mycobacterial activity, both alone and in synergistic combinations with the frontline anti-tuberculosis drug rifampicin. The addition of thiol groups by incorporating cysteine residues in the AMPs did not improve anti-mycobacterial activity against drug-susceptible and drug-resistant Mycobacterium tuberculosis, while the enhancement of peptide hydrophobicity by adding methionine residues increased the efficacy of the primary peptide against all strains tested, including clinically isolated multidrug-resistant mycobacteria. The peptide with the optimal composition M(LLKK)2M was bactericidal, and eradicated mycobacteria via a membrane-lytic mechanism as demonstrated by confocal microscopic studies. Mycobacteria did not develop resistance after multiple exposures to sub-lethal doses of the peptide. In addition, the peptide displayed synergism with rifampicin against both Mycobacterium smegmatis and Mycobacterium bovis BCG and additivity against M. tuberculosis. Moreover, such combination therapy is effective in delaying the emergence of rifampicin resistance. The ability to potentiate anti-TB drug activity, kill drug-resistant bacteria and prevent drug resistance highlights the potential utility of the peptide in combating multidrug-resistant TB. © 2013 Elsevier Ltd.
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1016/j.biomaterials.2013.11.035
dc.sourceScopus
dc.subjectα-Helical
dc.subjectAntimicrobial peptides
dc.subjectDrug resistance
dc.subjectMycobacterium tuberculosis
dc.subjectSynergy
dc.typeArticle
dc.contributor.departmentPHARMACY
dc.description.doi10.1016/j.biomaterials.2013.11.035
dc.description.sourcetitleBiomaterials
dc.description.volume35
dc.description.issue6
dc.description.page2032-2038
dc.description.codenBIMAD
dc.identifier.isiut000331018700025
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

51
checked on Jan 15, 2020

WEB OF SCIENCETM
Citations

48
checked on Jan 15, 2020

Page view(s)

74
checked on Jan 11, 2020

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.